Takeda Pharmaceutical Company Limited said it delivered FY2025 results that met its most recent guidance while preserving cash and cost discipline as it prepares for multiple near‑term product launches. Takeda reported FY2025 revenue of JPY 4,505.7 billion, down 1.7% year‑on‑year at actual exchange rates, which the company attributed to VYVANSE® loss of exclusivity partially offset by Growth & Launch Products.
Key financials and capital allocation
- FY2025 reported operating profit rose to JPY 408.8 billion, a 19.3% increase year‑on‑year, and operating margin expanded to 9.1% from 7.5% a year earlier.
- Adjusted free cash flow was JPY 684.5 billion, in line with forecast, and year‑end adjusted net debt/adjusted EBITDA was 2.6x; Takeda proposed an annual dividend of JPY 200 per share for FY2025.
- On a Core (non‑IFRS) basis, core revenue was JPY 4,505.7 billion (‑2.6% at CER), core operating profit was JPY 1,172.5 billion (up 0.8% AER, down 0.9% CER), and Core EPS rose 5.2% AER to an equivalent of 517 yen.
Pipeline progress and launch outlook
- Takeda highlighted positive Phase 3 readouts and regulatory progress for three late‑stage assets—oveporexton, rusfertide and zasocitinib—which the company said position it for regulatory approvals and launches in FY2026–2027.
- Oveporexton, an orexin agonist for narcolepsy type 1, and rusfertide, a hepcidin mimetic for polycythemia vera, both received Priority Review from the U.S. FDA and are being prepared for U.S. commercial launches in the second half of 2026, with regulatory filings completed in Japan and China for oveporexton.
- Zasocitinib is progressing toward a planned regulatory filing in 2026 and a commercial launch in the first half of 2027 as an oral treatment for psoriasis patients.
FY2026 outlook and guidance
- For FY2026 Takeda issued a revenue forecast of JPY 4,640.0 billion and set core operating profit (non‑IFRS) at JPY 1,160.0 billion, with management guidance expecting a 5%–8% decline in core operating profit at CER and a low‑single digit percentage decline in core revenue at CER.
- Takeda forecast adjusted free cash flow of JPY 650.0–750.0 billion and an annual dividend per share of JPY 204 for FY2026.
Management commentary
- CEO‑elect Julie Kim described FY2025 as “pivotal,” saying the company validated execution against development and regulatory milestones and is positioned for “three major launches planned in the next 12 months” and a “robust late‑stage pipeline,” framing Takeda’s growth strategy around near‑term launches and longer‑term blockbuster transitions.
- CFO Milano Furuta emphasized disciplined cost control that protected profitability and cash flow while funding launch readiness, and said FY2026 will focus on transforming operations, protecting profitability, successful launches and deleveraging to support long‑term investment.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!